Australia's Alchemia has announced plans to accelerate its work developing HyCAMP for colorectal cancer after reviewing preliminary Phase II data. The mid-stage study looked at the efficacy of HyCAMP compared with irinotecan. The experimental therapy is designed to improve drug targeting to increase efficacy and reduce toxicity. Researchers said that HyCAMP improved the median for "progression free survival" to 5.2 months from 2.4 months. Report | Release